Nephros (NASDAQ:NEPH) Upgraded at Zacks Research

Zacks Research upgraded shares of Nephros (NASDAQ:NEPH) to a hold rating in a research report released on Monday morning,Zacks.com reports.

NEPH has been the topic of a number of other research reports. Northland Securities began coverage on shares of Nephros in a research report on Friday, July 17th. They set a “market perform” rating and a $4.00 price objective on the stock. Weiss Ratings lowered shares of Nephros from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Nephros currently has a consensus rating of “Hold” and an average target price of $5.00.

Nephros Stock Performance

Shares of Nephros stock opened at $3.65 on Monday. The stock has a market cap of $39.64 million, a price-to-earnings ratio of 52.15 and a beta of 1.49. The stock has a 50 day moving average price of $3.47 and a 200-day moving average price of $3.62. Nephros has a one year low of $2.66 and a one year high of $6.42.

Nephros (NASDAQ:NEPH) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $5.21 million for the quarter, compared to analyst estimates of $5.02 million. Nephros had a return on equity of 7.66% and a net margin of 4.06%. Sell-side analysts predict that Nephros will post 0.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nephros

A number of institutional investors and hedge funds have recently modified their holdings of the business. Topline Capital Management LLC boosted its holdings in Nephros by 13.1% during the 2nd quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock valued at $1,953,000 after acquiring an additional 55,360 shares during the period. Renaissance Technologies LLC increased its stake in Nephros by 25.8% in the fourth quarter. Renaissance Technologies LLC now owns 103,772 shares of the company’s stock worth $506,000 after purchasing an additional 21,272 shares during the period. Geode Capital Management LLC increased its stake in Nephros by 3.2% in the second quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock worth $381,000 after purchasing an additional 2,898 shares during the period. HighTower Advisors LLC lifted its position in shares of Nephros by 7.2% during the fourth quarter. HighTower Advisors LLC now owns 59,710 shares of the company’s stock worth $291,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. lifted its position in shares of Nephros by 262.3% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 50,000 shares of the company’s stock worth $244,000 after purchasing an additional 36,200 shares during the last quarter. 41.10% of the stock is owned by institutional investors.

Key Nephros News

Here are the key news stories impacting Nephros this week:

• Positive Sentiment: Zacks Research upgraded Nephros to Hold, which can be seen as a modestly improved view on the stock and may help support sentiment. Tickerreport.com
• Neutral Sentiment: Northland Securities reiterated a Market Perform rating and $4.00 price target, suggesting the firm sees limited near-term upside or downside from current levels. The note also laid out earnings estimates calling for small profits in 2026 and stronger earnings growth in 2027.
• Neutral Sentiment: The company’s latest earnings report was roughly in line with expectations, with Q1 EPS of $0.01 and revenue of $5.21 million topping estimates slightly, which supports the view that Nephros is executing steadily but not delivering a major surprise.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.